Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Receives $16.00 Consensus Target Price from Analysts

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) has been assigned a consensus rating of “Hold” from the five research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $16.00.

NTHI has been the subject of a number of recent analyst reports. Weiss Ratings cut shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, June 24th. Wall Street Zen lowered shares of Neonc Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Maxim Group assumed coverage on shares of Neonc Technologies in a research note on Monday, May 18th. They set a “buy” rating and a $20.00 price objective on the stock. Alliance Global Partners began coverage on shares of Neonc Technologies in a report on Tuesday, May 19th. They set a “buy” rating and a $13.00 price objective for the company. Finally, BTIG Research reissued a “buy” rating and issued a $15.00 target price on shares of Neonc Technologies in a report on Tuesday, May 26th.

Insider Buying and Selling at Neonc Technologies

In other Neonc Technologies news, CEO Thomas C. Chen bought 12,757 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were bought at an average price of $5.49 per share, for a total transaction of $70,035.93. Following the completion of the acquisition, the chief executive officer owned 13,705 shares of the company’s stock, valued at approximately $75,240.45. This trade represents a 1,345.68% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Amir F. Heshmatpour bought 12,000 shares of the stock in a transaction dated Friday, August 14th. The stock was acquired at an average price of $3.79 per share, with a total value of $45,480.00. Following the completion of the purchase, the chief executive officer owned 3,084,000 shares of the company’s stock, valued at $11,688,360. This represents a 0.39% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 36,757 shares of company stock valued at $178,486.

Institutional Investors Weigh In On Neonc Technologies

A number of hedge funds have recently added to or reduced their stakes in NTHI. Barclays PLC increased its position in Neonc Technologies by 5,314.8% in the 4th quarter. Barclays PLC now owns 9,151 shares of the company’s stock valued at $76,000 after acquiring an additional 8,982 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Neonc Technologies during the fourth quarter worth approximately $124,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Neonc Technologies during the fourth quarter worth approximately $126,000. Royal Bank of Canada bought a new stake in shares of Neonc Technologies during the first quarter valued at approximately $247,000. Finally, Global Retirement Partners LLC bought a new stake in shares of Neonc Technologies during the second quarter valued at approximately $126,000.

Neonc Technologies Stock Up 2.6%

Shares of NTHI stock opened at $4.68 on Friday. Neonc Technologies has a one year low of $3.01 and a one year high of $12.99. The stock has a fifty day moving average price of $4.14 and a 200 day moving average price of $5.95.

Neonc Technologies (NASDAQ:NTHI) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.